Aro Biotherapeutics – a clinical-stage biotechnology company pioneering the development of tissue-targeted genetic medicines – recently announced it has secured $41.5 million in a Series B funding round.
The funding round was led by Cowen Healthcare Investments, with participation from existing investors from Aro’s Series A financing round in 2020, including Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Northpond Ventures, Healthcap and BVF Partners, L.P. In connection with the funding, Christopher Picariello, President of JJDC, has joined Aro’s Board of Directors.
Aro will use the funding round to advance the development of its lead program, ABX1100, a novel potential treatment for patients with Pompe Disease. And Aro recently announced the start of a first-in-human with ABX1100, and the Company anticipates that initial data from this study will be presented in 2024. In addition, the Series B funding will support new Centyrin-siRNA conjugate programs focused on the discovery of new therapies for autoimmune disorders.
KEY QUOTE:
“We are appreciative of the support provided by this syndicate of leading life science industry investors. Aro is well positioned to advance our pipeline and progress the field by leveraging our Centyrin platform to enable efficient and tissue-targeted delivery of siRNA. This funding enables us to continue to pursue our mission and bring new medicines to patients who desperately need more effective treatments.”
— Susan Dillon, Ph.D., Chief Executive Officer of Aro
